Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kelly Blackmon

Nurse Practitioner Waycross, GA Nurse Practitioner

NPI 1992110688 CMS profile 10912423

1706 Alice St, Waycross, GA 31501

Open in the dashboard

General payments

$3,130

58 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Blackmon of Waycross, GA is reported in the CMS Open Payments database as having received $3,130 across 58 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $418 9
2024 General $23 1
2023 General $2,328 30
2022 General $257 12
2021 General $104 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Blackmon
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kelly Blackmon were reported at $418. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kelly Blackmon Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $104 $135 $40–$426 $132
2022 $257 $152 $48–$470 $149
2023 $2,328 $166 $54–$529 $160
2024 $23 $173 $55–$556 $164
2025 $418 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $1,736 18 payments
  2. Abbott Laboratories $274 2 payments
  3. Atricure, Inc. $256 5 payments
  4. Janssen Biotech, Inc. $231 5 payments
  5. Exelixis Inc. $95 1 payment
  6. Baxter Healthcare $83 4 payments
  7. Myriad Genetic Laboratories, Inc. $71 2 payments
  8. KCI USA, Inc $56 3 payments
  9. AstraZeneca Pharmaceuticals LP $48 2 payments
  10. Boston Scientific Corporation $44 2 payments
  11. Other $237 14 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,697 47 payments
  2. Travel and Lodging $1,192 8 payments
  3. Education $240 3 payments
Products named General payments · program years 2021–2025
  1. COREVALVE EVOLUT R $1,646 17 payments
  2. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $256 5 payments
  3. RYBREVANT $191 3 payments
  4. ATRICLIP LAA EXCLUSION SYSTEM $159 3 payments
  5. MITRACLIP Vascular $139 1 payment
  6. MITRACLIP Vascular $134 1 payment
  7. CARVYKTI $125 1 payment
  8. myRisk $71 2 payments
  9. PREVELEAK $50 2 payments
  10. ANDEXXA $48 2 payments
  11. Other $486 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

163

Median for Nurse Practitioner: 389

Drug cost

$784

Median for Nurse Practitioner: $21,885

Branded share of claims

15.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pantoprazole Sodium Generic 28 $185
Clopidogrel Clopidogrel Bisulfate Brand 25 $126
Trazodone Hcl Generic 29 $107
Metoprolol Tartrate Generic 25 $94
Prednisone Generic 14 $86
Sertraline Hcl Generic 19 $72
Tramadol Hcl Generic 11 $64
Clonazepam Generic 12 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$20,122

Medicare's payments for the services billed

Medicare patients

102

Average age 79

Services billed

251

60 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Alzheimer's or dementia 51%
Depression 50%
Arthritis 45%
Diabetes 43%
Ischemic heart disease 37%
Chronic kidney disease 36%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record